Mizuho lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $10 from $30 and keeps an Outperform rating on the shares post the Q1 report and 2025 revenue guidance cut. The firm issued a “fairly hard reset, and may be just what the Street needs to finally move on with this stock and take a fresh look,” the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics downgraded to Hold from Buy at Truist
- Iovance Biotherapeutics price target lowered to $4 from $5 at Barclays
- Iovance Biotherapeutics’ Earnings Call: Mixed Sentiments and Future Prospects
- Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
- Iovance Biotherapeutics price target lowered to $5 from $10 at TD Cowen